99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of MYGN Investors. Click "Join this Class Action" above.

Attorneys

Myriad Genetics, Inc.

Join Class Action »

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Myriad Genetics, Inc. (NASDAQ: MYGN) from September 2, 2016 through August 13, 2019 (the “Class Period”). The lawsuit seeks to recover damages for Myriad Genetics, Inc. investors under the federal securities laws.

If you bought Myriad Genetics, Inc. securities between September 2, 2016 through August 13, 2019, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN

New York, N.Y., October 2, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Myriad Genetics, Inc. (NASDAQ: MYGN) between September 2, 2016 and August 13, 2019, inclusive (the “Class Period”). To join the MYGN class action, go to http://zhanginvestorlaw.com/cases/myriad-genetics-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, throughout the Class Period 1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (3) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (4) Myriad’s acquisition of Counsyl – and thereby, Foresight – caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company’s revenue (5) as a result, Myriad’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 26, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/myriad-genetics-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.